CD169抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CD169 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD169 mouse mAb (green) and negative control (red).    

  
  

CD169. also known as Siglec-1 or sialoadhesin, is a cell surface receptor belonging to the sialic acid-binding immunoglobulin-like lectin (Siglec) family. It is primarily expressed on specific subsets of tissue-resident macrophages, such as lymph node sinus macrophages and splenic red pulp macrophages. Structurally, CD169 is a type I transmembrane protein with multiple immunoglobulin-like domains, enabling its N-terminal region to bind sialylated glycans on neighboring cells or pathogens. Functionally, it plays roles in cell-cell interactions, innate immune responses, and modulation of inflammation. CD169 has been implicated in both promoting and suppressing immune activation, depending on context—facilitating antigen capture/presentation to lymphocytes or inducing tolerance via immunosuppressive signaling.

CD169 antibodies are critical tools for studying macrophage biology and immune regulation. They help identify CD169-expressing macrophage subsets in tissues and dissect their involvement in infections (e.g., HIV, influenza), autoimmune diseases, and cancer. For instance, CD169+ macrophages act as viral reservoirs in HIV or enhance pathogen clearance in bacterial infections. These antibodies are widely used in flow cytometry, immunohistochemistry, and functional assays to explore CD169's dual roles in immunity. Additionally, CD169-targeting therapies are under investigation, including antibody-drug conjugates for cancer or strategies to block viral entry. As a biomarker, CD169 expression correlates with disease progression in conditions like lupus or fibrosis. Its study continues to reveal insights into macrophage heterogeneity and therapeutic opportunities.